Published in final edited form as:

J Card Fail. 2009 November ; 15(9): 756–762. doi:10.1016/j.cardfail.2009.05.012.

The Lowest VE/VCO₂ Ratio during Exercise as a Predictor of Outcomes in Patients with Heart Failure

Jonathan Myers, PhD, Ross Arena, PhD, Ricardo Oliveira, PhD, Daniel Bensimhon, MD, Leon Hsu, BS, Paul Chase, MEd, Marco Guazzi, MD, PhD, Peter Brubaker, PhD, Brian Moore, MS, Dalane Kitzman, MD, and Mary Ann Peberdy, MD

Veterans Affairs Palo Alto Health Care System, Virginia Commonwealth University, LeBauer Cardiovascular Research Foundation, University of Milano, Wake Forest University School of Medicine, and Stanford University, Palo Alto, CA

Abstract

Background—The lowest VE/VCO₂ ratio during exercise has been suggested to be the most stable and reproducible marker of ventilatory efficiency in patients with heart failure (HF). However, the prognostic power of this index is unknown.

Methods—847 HF patients underwent cardiopulmonary exercise testing (CPX) and were followed for 3 years. The associations between the lowest VE/VCO₂ ratio, peak VO₂, the VE/VCO₂ slope and major events (death or transplantation) were evaluated using proportional hazards analysis; adequacy of the predictive models was assessed using Akaike information criterion (AIC) weights.

Results—There were 147 major adverse events. In multivariate analysis, the lowest VE/VCO₂ ratio (higher ratio associated with greater risk) was similar to the VE/VCO₂ slope in predicting risk (hazard ratios [HR] per unit increment 2.0, 95% CI 1.1–3.4, and 2.2, 95% CI 1.3–3.7, respectively, $p < 0.01$), followed by peak VO₂ (HR 1.6, 95% CI 1.1–2.4, $p = 0.01$). Patients exhibiting abnormalities for all 3 responses had an 11.6-fold higher risk. The AIC weight for the three variables combined (0.94) was higher than any single response or any combination of two. The model including all 3 responses remained the most powerful after adjustment for beta blocker use, type of HF, and after applying different cutpoints for high risk.

Conclusion—The lowest VE/VCO₂ ratio adds to the prognostic power of conventional CPX responses in HF.

Cardiopulmonary exercise testing (CPX) has been widely used the last two decades to quantify functional limitations and estimate risk for adverse outcomes in patients with chronic heart failure (HF). Maximal oxygen uptake (peak VO₂) is considered the gold standard for quantifying an individual's cardiopulmonary limits, and numerous studies have

Address for correspondence: Jonathan Myers, Ph.D., VA Palo Alto Health Care System Cardiology Division – 111C 3801 Miranda Ave. Palo Alto, CA 94304 Phone: 650-493-5000 ext. 6-4661 Fax: 650-852-3473, drj993@aol.com.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

demonstrated the prognostic utility of this measurement (1). In recent years however, a great deal of interest has arisen regarding other CPX markers of risk; these have largely focused on indices of ventilatory inefficiency. For example, over the last decade, the VE/VCO_2 slope, expressed as the slope of the linear relation between minute ventilation (VE) and carbon dioxide production (VCO_2), has been demonstrated to be a more powerful predictor of risk for mortality, hospitalization, and other outcomes than peak VO_2 (1–5). There have also been other expressions of ventilatory inefficiency associated with poor outcomes in HF, including the oxygen uptake efficiency slope (OUES) (6), VO_2 kinetics (7), end-tidal CO_2 pressure (Pet CO_2) at rest and during exercise (8,9), VO_2 in recovery from exercise (10), and oscillatory ventilation (11). These indices have been shown to predict risk independently and to complement peak VO_2 in estimating prognosis in patients with HF (1).

While indices of ventilatory inefficiency and their association with outcomes in HF have been the topic of a great deal of recent investigation, the optimal multivariate application of these responses for estimating prognosis has not been established. Sun and colleagues (12) recently studied the influence of age, gender, body size, fitness, testing site, and exercise mode on ventilatory efficiency in 474 healthy adults. They observed that, relative to other indices of ventilatory inefficiency, the lowest VE/VCO_2 ratio during exercise was the most reproducible and stable response across laboratory sites, exercise mode, gender and age. They concluded that the lowest VE/VCO_2 ratio represented the preferred noninvasive index to estimate ventilatory inefficiency. Although the VE/VCO_2 slope has become well-established as a marker of prognosis in recent years (1–5), it has been suggested that the VE/VCO_2 ratio may be a more stable marker of ventilatory inefficiency because the VE/VCO_2 slope is subject to transient hyperventilation early in exercise (due to anxiety) and is affected by metabolic acidosis during high levels of exercise (12). Given the suggestion that it is a more stable marker of ventilatory efficiency, it would be useful to determine the prognostic utility of the VE/VCO_2 ratio in patients with HF. To our knowledge, the prognostic value of this index has not been studied. In the current study, we evaluated this index along with the well-established indices of risk, peak VO_2 and the VE/VCO_2 slope, and their association with outcomes in a group of patients with stable HF.

Methods

This study was a multicenter, retrospective analysis including HF patients from the exercise laboratories at the VA Palo Alto Health Care System, Palo Alto, California, San Paolo Hospital, Milan, Italy, Virginia Commonwealth University, Richmond, Virginia, Wake Forrest University Baptist Medical Center, Winston-Salem, North Carolina, and the LeBauer Cardiovascular Research Foundation, Greensboro, North Carolina. A total of 847 consecutive patients with stable chronic HF, tested between 3/18/1993 and 11/15/2007, were included. Subjects received routine follow-up care, and all surviving patients were followed for a minimum of 3 years. Inclusion criteria consisted of a diagnosis of HF (13) and evidence of left ventricular systolic (ejection fraction <40%) and/or diastolic dysfunction by two-dimensional echocardiography obtained within one month of exercise testing. Systolic dysfunction was present in 81.3% of the sample. Subjects received routine follow-up care at the four institutions included in the study. All subjects completed a written informed consent and institutional review board approval was obtained at each institution.

CPX Procedure and Data Collection

Symptom-limited CPX was performed on all patients using treadmill or cycle ergometer ramping protocols (14). A treadmill was used for testing in the American centers while a cycle ergometer was used in the European center. We previously observed that optimal peak VO_2 and VE/VCO_2 slope threshold values for estimating prognosis were similar irrespective of mode of exercise in patients with HF (15). Ventilatory expired gas analysis was performed using a metabolic cart at all four centers (Medgraphics CPX-D or ULTIMA PFX, Minneapolis, MN, ORCA Diagnostics, Santa Barbara, CA, Parvo Medics TrueOne 2400, Sandy, UT or Sensormedics Vmax29, Yorba Linda, CA). Before each test, the equipment was calibrated in a standard fashion using reference gases. A standard 12-lead electrocardiogram was obtained at rest, each minute during exercise, and for at least 5 minutes during the recovery phase; blood pressure was measured using a standard cuff sphygmomanometer.

Minute ventilation (VE , BTPS), oxygen uptake (VO_2 , STPD), carbon dioxide production (VCO_2 , STPD) and other CPX variables were acquired breath-by-breath and averaged over 10- or 15-second intervals. Peak VO_2 and peak respiratory exchange ratio (RER) were expressed as the highest averaged samples obtained during the exercise test. VE and VCO_2 responses throughout exercise were used to calculate the VE/VCO_2 slope via least squares linear regression ($y = mx + b$, $m = \text{slope}$). Previous work by our group and others has shown this method of calculating the VE/VCO_2 slope to be optimal for estimating prognosis (16,17). The ratio of VE to VCO_2 was calculated each minute during exercise; the lowest minute sample was taken as the lowest VE/VCO_2 ratio.

Endpoints

A composite variable including total mortality and cardiac transplantation was the primary endpoint. Left ventricular assist device (LVAD) implantation was considered as a component of the composite endpoint, but no LVAD implantations occurred during the 3-year follow-up period. All survivors were followed for a minimum of 3 years. Ninety seven per cent of the outcomes were total mortality. The most common causes of mortality, as per discharge diagnosis, were sudden cardiac death (45%) and worsening HF (55%). Subjects were followed for major cardiac-related events following their exercise test using the Social Security Death Index and hospital and outpatient medical chart review. Follow-up was performed by the HF program at each respective institution, providing a high likelihood that all major events were captured. Clinicians conducting the CPX were not involved in decisions regarding cause of death or heart transplant/LVAD implantation.

Statistical Analysis

NCSS software (Kayesville, UT) was used to perform unpaired t-tests for comparisons of continuous variables and chi-square tests to compare categorical variables between those who achieved above vs. below each CPX threshold. Receiver operating characteristic (ROC) curve analysis, using the composite endpoint at 3 years, was used to define optimal threshold values for each CPX response. Optimal thresholds were chosen using the “shortest distance to one” criterion on the ROC curve (18). Z-tests were used to assess whether each ROC curve differed from chance for each of the CPX responses. Optimal thresholds for

abnormal for each of the CPX variables were as follows: VE/VCO₂ slope (< 34), peak VO₂ (< 14 ml/kg/min), and lowest VE/VCO₂ ratio (< 33). Cox proportional hazards analysis was used to determine age- and CPX (VE/VCO₂ slope, peak VO₂, and lowest VE/VCO₂ ratio) - adjusted hazard ratios for the variables included in the model, each expressed dichotomously using the threshold value. The proportional hazard assumptions were confirmed for each variable using the scaled Schoenfeld residual. The linearity of the relation between abnormal responses for peak VO₂, the VE/VCO₂ slope, and the lowest VE/VCO₂ ratio was confirmed by plotting each response against mortality. The Akaike Information Criterion (AIC) method was used to compare the predictive accuracy of the models (19). The AIC and proportional hazards analyses were repeated using different cutpoints for high risk and after adjustment for beta blocker use.

Results

The study sample comprised 602 males and 245 females with HF; 331 (39%) had an ischemic etiology. Table 1 shows the mean demographic data, exercise test responses, and univariate hazard ratios using continuous data for the study group. The mean age of the cohort was 57 ± 14 years and the mean body mass index (BMI) was 28.4 ± 5.9 kg/m². The key exercise test responses, including peak heart rate, peak VO₂, peak VO₂ as a percentage of age-predicted, the VE/VCO₂ slope and the lowest VE/VCO₂ ratio all yielded significant hazard ratios.

There were 147 events (143 deaths and 4 transplantations) over the follow-up period. Areas under the ROC curves and optimal thresholds for peak VO₂, the VE/VCO₂ slope, and lowest VE/VCO₂ ratio are presented in Table 2. The optimal thresholds for peak VO₂, the VE/VCO₂ slope, and lowest VE/VCO₂ ratio were ≤ 14 ml/kg/min, ≤ 34 , and ≤ 33 , respectively. A Kaplan-Meier survival curve illustrating patients achieving ≤ 33 and > 33 for the lowest VE/VCO₂ ratio is shown in Figure 1; those with a lowest VE/VCO₂ ratio ≤ 33 had a significantly higher mortality than those with a value > 33 . Demographic data and exercise test responses among patients achieving below and above the optimal threshold values for the lowest VE/VCO₂ ratio, the VE/VCO₂ slope, and peak VO₂ are shown in Table 3. Peak VO₂ and maximal heart rate were significantly lower and the lowest VE/VCO₂ ratio and VE/VCO₂ slope were significantly higher among patients achieving an abnormal value for each response.

Using the optimal thresholds, the lowest VE/VCO₂ ratio and the VE/VCO₂ slope had similar prognostic power by univariate analysis (hazard ratios [HR] 3.45, 95% CI 2.1–5.6, and 3.45, 95% CI 2.2–5.6, respectively, $p < 0.001$), followed by peak VO₂ (HR 2.1, 95% CI 1.4–3.1, $p < 0.001$). By age-adjusted multivariate analysis, the respective HRs were 2.0 (95% CI 1.1–3.4, $p = 0.02$), 2.2 (95% CI 1.3–3.7, $p = 0.002$), and 1.6 (1.1–2.4, $p = 0.01$). These results did not change appreciably when adjusted for type of HF (systolic/diastolic dysfunction or ischemic/non-ischemic). Similarly, neither the proportional hazards results nor the ROC cutpoints changed appreciably when patients taking beta blockers were analyzed separately or when the follow-up times were standardized to a range of time points, including 2, 3, or 4 years.

Table 4 presents age-adjusted AIC weights for models using peak VO_2 , the VE/VCO_2 slope, and lowest VE/VCO_2 ratio independently and in various combinations. The model including all 3 variables had the highest predictive value (0.94, indicating a 94% probability of being the strongest model). The model including all 3 responses remained the most powerful after adjustment for beta blocker use and after applying different cutpoints for high risk.

Table 5 presents relative risks associated with abnormal peak VO_2 , VE/VCO_2 slope, lowest VE/VCO_2 ratio, and their combination. Risk for an adverse event was highest when all 3 responses were abnormal. Patients exhibiting abnormalities for all 3 responses had an annual event rate of approximately 14%, and an 11.6-fold higher risk compared to patients whose responses were normal.

Discussion

The CPX has been widely applied over the last two decades as a tool for risk stratifying patients with HF (1). The prognostic applications of the CPX have been expanded in recent years to include markers of ventilatory inefficiency and hemodynamic responses in addition to peak VO_2 (1–11). Most notably, the VE/VCO_2 slope has consistently been shown to be a more powerful predictor of risk than peak VO_2 in these patients (1,3,20). Other markers of ventilatory inefficiency, such as oscillatory ventilation, the OUES, an early ventilatory threshold, and low resting or exercise end-tidal CO_2 pressure, have been shown to be independent prognostic markers or to complement peak VO_2 in estimating prognosis in patients with HF (1,2,4,5,8,9,11,21). While multivariable efforts to optimize these markers for estimating risk in HF have been the topic of numerous investigations in recent years (1,21,22), the optimal expression of ventilatory inefficiency has not been fully explored. Because it was recently reported that the lowest VE/VCO_2 ratio during exercise (a different expression of ventilatory inefficiency than the VE/VCO_2 slope) was the most reproducible and stable response relative to other indices of ventilatory inefficiency (12), we sought to determine its prognostic utility.

Our sample comprised a typical heterogeneous group of patients with CHF, with a mean peak VO_2 of 15.1 ml/kg/min, a mean LVEF of 32%, and with 67% of subjects taking a beta blocker. Because the prognostic power of peak VO_2 and the VE/VCO_2 slope have been well established using conventional proportional hazards methods (1,22), the additive predictive accuracy afforded by adding the lowest VE/VCO_2 ratio was assessed using a model selection method designed to compare multiple candidate models, and determine which most accurately describes the data (the AIC weight). We observed that adding the lowest VE/VCO_2 ratio to the more established markers of prognosis (peak VO_2 and the VE/VCO_2 slope) provided the highest prediction of risk for the composite outcome (mortality and transplantation). Including the 3 variables together yielded a 94% probability that the model was superior; this contrasts the negligible probability when using any one of the variables alone (Table 4). It is also noteworthy that the highest risk was generated in the model that included peak VO_2 , the VE/VCO_2 slope, and the lowest VE/VCO_2 ratio together (Table 5). When all 3 of the responses were abnormal, a nearly 12-fold risk of having an event was observed (Table 5). Finally, the results were not influenced by beta blocker use; the findings

were similar when the models were controlled for beta blocker use or when patients not taking beta blockers were excluded (33% of the sample).

There are several clinically salient applications from the current study. The lowest VE/VCO₂ ratio is a readily available CPX response that appears to strongly predict risk in HF, and one that complements the conventional markers of risk; peak VO₂ and the VE/VCO₂ slope. The lowest VE/VCO₂ ratio has been suggested to be the preferred non-invasive index of ventilatory efficiency based on its low variability, high reproducibility, and stability across centers and exercise modes (12). The lowest VE/VCO₂ ratio will occur at or just below the ventilatory threshold (12,23) and is therefore less influenced by the variation that accompanies hyperventilation at higher levels of exercise. Given the growing awareness of the need to apply statistical techniques to develop evidence-based multivariable approaches for improving clinical decision-making (24), the application of the 3 CPX responses used in the current study would appear to optimize the estimation of risk in patients with HF; each provided independent risk information, and the AIC model that included all 3 variables (Table 5) demonstrated that each response augmented the predictive power of the model (19). It is also noteworthy that both the VE/VCO₂ slope and the lowest VE/VCO₂ ratio were stronger predictors of risk than peak VO₂, reinforcing the concept emphasized in recent studies and guidelines that measures of ventilatory inefficiency should be included in the risk paradigm when evaluating patients with HF (1,21,22,25).

The VE/VCO₂ ratio (commonly termed the *ventilatory equivalent for CO₂*) differs from the index that has been widely used to estimate risk in recent years, the VE/VCO₂ slope, in that it is derived at a single time point during exercise. In accordance with the alveolar gas equation, a heightened VE/VCO₂ ratio may occur due to a low PaCO₂, an abnormally high dead space fraction of tidal volume (Vd/Vt), or both. In patients with HF, PaCO₂ changes only slightly during exercise (26); therefore a heightened VE/VCO₂ ratio is likely due to a high dead space ventilation (high Vd/Vt) due to poor perfusion of ventilated alveoli. One of the hallmarks of HF is an impaired cardiac output response to exercise (27), which underlies the mismatching between ventilation and perfusion in the lungs (and therefore a heightened Vd/Vt). Thus, a higher VE/VCO₂ ratio will reflect a more impaired cardiac output response to exercise. Although the prognostic value of the lowest VE/VCO₂ ratio has not been studied to our knowledge, several studies have addressed the prognostic utility of the *peak* VE/VCO₂ ratio in patients with HF. Arena and colleagues (28) reported that the VE/VCO₂ slope and the peak exercise VE/VCO₂ ratio provided similar prognostic power in terms of predicting mortality or hospitalization in patients with HF (ROC curves 0.87 and 0.85 for the VE/VCO₂ slope and ratio, respectively). Mejhert et al (29) reported that the peak VE/VCO₂ ratio was a stronger predictor of mortality than peak VO₂ and the VE/VCO₂ slope; patients with a heightened peak VE/VCO₂ ratio had a nearly 7-fold higher risk of mortality. Using the VE/VCO₂ ratio at the anaerobic threshold (analogous to the *lowest* VE/VCO₂ ratio), MacGowan and colleagues (30) observed that an abnormal response (>50) provided prognostic information that complemented peak VO₂; 82% of patients with a VE/VCO₂ ratio at the anaerobic threshold >50 and a peak VO₂ 15 ml/kg/min died during a mean follow-up of 552 days. Robbins et al (31) reported that the VE/VCO₂ ratio at the anaerobic threshold was similar to the peak VE/VCO₂ ratio in predicting mortality.

Limitations

Our study was limited by the fact that the sample was predominately male with moderate disease. As with any approach, the findings must be validated in different populations of patients with HF. In addition, there has recently been a variety of CPX variables related to ventilatory inefficiency that have been applied for the purposes of predicting outcomes in HF (eg. oscillatory ventilation, PetCO_2 , VO_2 kinetics during exercise and VO_2 in recovery) (1); the role that the lowest VE/VCO_2 ratio plays in supplementing these indices requires further exploration.

Summary

The lowest VE/VCO_2 ratio during exercise is a powerful marker of prognosis in patients with HF, and provides prognostic information that is independent from peak VO_2 and the VE/VCO_2 slope. The lowest VE/VCO_2 ratio complements peak VO_2 and the VE/VCO_2 slope when estimating risk in patients with HF and should be considered when performing CPX to determine prognosis.

References

1. Arena R, Myers J, Guazzi M. The clinical and research applications of aerobic capacity and ventilatory efficiency in heart failure: An evidence-based review. *Heart Failure Reviews*. 2008; 13:245–269. [PubMed: 17987381]
2. Gitt AK, Wasserman K, Kilkowski C, Kleemann T, Kilkowski A, Bangert M, et al. Exercise anaerobic threshold and ventilatory efficiency identify heart failure patients for high risk of early death. *Circulation*. 2002; 106(24):3079–3084. [PubMed: 12473555]
3. Arena R, Myers J, Abella J, Peberdy MA, Bensimhon D, Chase P, et al. Development of a ventilatory classification system in patients with heart failure. *Circulation*. 2007; 115(18):2410–2417. [PubMed: 17452607]
4. Arena R, Myers J, Hsu L, Peberdy MA, Pinkstaff S, Bensimhon D, Chase P, Vicenzi M, Guazzi M. The minute ventilation/carbon dioxide production slope in prognostically superior to the oxygen uptake efficiency slope. *J Cardiac Fail*. 2007; 13:462–469.
5. Corra U, Mezzani A, Bosimini E, Scapellato F, Imparato A, Giannuzzi P. Ventilatory response to exercise improves risk stratification in patients with chronic heart failure and intermediate functional capacity. *Am Heart J*. 2002; 143:418–426. [PubMed: 11868046]
6. Davies LC, Wensel R, Georgiadou P, Cicoira M, Coats AJ, Piepoli MF, Francis DP. Enhanced prognostic value from cardiopulmonary exercise testing in chronic heart failure by non-linear analysis: Oxygen uptake efficiency slope. *Eur Heart J*. 2006; 27:684–690. [PubMed: 16338939]
7. Rickli H, Kiowski W, Brehm M, Weilenmann D, Schalcher C, Bernheim A, Oechslin E, Brunner-La Rocca HP. Combining low-intensity and maximal exercise test results improves prognostic prediction in chronic heart failure. *J Amer Coll Cardiol*. 2003; 42:116–122. [PubMed: 12849670]
8. Arena R, Guazzi M, Myers J. Prognostic value of end-tidal carbon dioxide during exercise testing in heart failure. *Int J Cardiol*. 2007; 117:103–108. [PubMed: 16843545]
9. Arena R, Peberdy MA, Myers J, Guazzi M, Tevald M. Prognostic value of resting end-tidal carbon dioxide in patients with heart failure. *Int J Cardiol*. 2006; 109:351–358. [PubMed: 16046017]
10. De Groote P, Millaire A, Decoulx e, Nogue O, Guimier P, Ducloux G. Kinetics of oxygen consumption during and after exercise in patients with dilated cardiomyopathy. *J Am Coll Cardiol*. 1996; 28:168–175. [PubMed: 8752810]
11. Arena R, Myers J, Abella J, Peberdy MA, Pinkstaff S, Bensimhon D, Chase P, Guazzi M. Prognostic value of timing and duration characteristics of exercise oscillatory ventilation in patients with heart failure. *J Heart Lung Transplant*. 2008; 27:341–347. [PubMed: 18342759]

12. Sun XG, Hansen JE, Garatachea N, Storer TW, Wasserman K. Ventilatory efficiency during exercise in healthy subjects. *Am J Respir Crit Care Med*. 2002; 166:1443–1448. [PubMed: 12450934]
13. Hunt SA. American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). *J Am Coll Cardiol*. 2005; 46:e1–82. [PubMed: 16168273]
14. Myers J, Buchanan N, Walsh D, Kraemer M, McAuley P, Hamilton-Wessler M, Froelicher VF. Comparison of the ramp versus standard exercise protocols. *J Am Coll Cardiol*. 1991; 17:1334–1342. [PubMed: 2016451]
15. Arena R, Guazzi M, Myers J, Ann Peberdy M. Prognostic characteristics of cardiopulmonary exercise testing in heart failure: comparing American and European models. *Eur J Cardiovasc Prev Rehabil*. 2005; 12:562–567. [PubMed: 16319546]
16. Arena R, Myers J, Aslam S, Varughese EB, Peberdy MA. Technical considerations related to the minute ventilation/carbon dioxide output slope in patients with heart failure. *Chest*. 2003; 124(2): 720–727. [PubMed: 12907564]
17. Bard RL, Gillespie BW, Clarke NS, Egan TG, Nicklas JM. Determining the best ventilatory efficiency measure to predict mortality in patients with heart failure. *J Heart Lung Transpl*. 2006; 25(5):589–595.
18. Perkins NJ, Schisterman EF. The inconsistency of “optimal” cut-points using two ROC based criteria. *Am J Epidemiol*. 2006; 163:670–675. [PubMed: 16410346]
19. Wagenmakers EJ, Farrell S. AIC model selection using Akaike weights. *Psychonomic Bulletin & Rev*. 2004; 11:192–196.
20. Arena R, Myers J, Aslam SS, Varughese EB, Peberdy MA. Peak VO_2 and VE/VCO_2 slope in patients with heart failure: a prognostic comparison. *Am Heart J*. 2004; 147(2):354–360. [PubMed: 14760336]
21. Myers J, Arena R, Dewey F, Bensimhon D, Abella J, Hsu L, et al. A cardiopulmonary exercise testing score for predicting outcomes in patients with heart failure. *Am Heart J*. 2008 in press.
22. Ingle L. Theoretical rational and practical recommendations for cardiopulmonary exercise testing in patients with chronic heart failure. *Heart Fail Rev*. 2007; 12:12–22. [PubMed: 17393306]
23. Wasserman, K.; Hansen, JE.; Sue, DY.; Casaburi, R.; Whipp, BJ. Principles of exercise testing and interpretation. 4. Baltimore: Lippincott, Williams & Wilkins; 2004. p. 97p. 98
24. Ashley E, Myers J, Froelicher VF. Exercise testing scores as an example of better decisions through science. *Med Sci Sports Exerc*. 2002; 34:1391–1398. [PubMed: 12165697]
25. Piepoli MF, Corrà U, Agostoni PG, Belardinelli R, Cohen-Solal A, Hambrecht R, Vanhees L. Task Force of the Italian Working Group on Cardiac Rehabilitation and Prevention. Statement on cardiopulmonary exercise testing in chronic heart failure due to left ventricular dysfunction. Recommendations for performance and interpretation. *Eur J Cardiovasc Prev Rehabil*. 2006; 13:300–311. [PubMed: 16926657]
26. Wasserman K, Zhang YY, Gitt A, Belardinelli R, Koike A, et al. Lung function and exercise gas exchange in chronic heart failure. *Circulation*. 1997; 96:2221–2227. [PubMed: 9337193]
27. Myers J, Froelicher VF. Hemodynamic determinants of exercise capacity in chronic heart failure. *Ann Internal Med*. 1991; 115:377–386. [PubMed: 1863029]
28. Arena R, Myers J, Aslam SS, Varughese EB, Peberdy MA. Prognostic comparison of the minute ventilation/carbon dioxide production ratio and slope in patients with heart failure. *Heart Drug*. 2004; 4:133–139.
29. Mejhert M, Linder-Klingsell E, Edner M, Kahan T, Persson H. Ventilatory variables are strong prognostic markers in elderly patients with heart failure. *Heart*. 2002; 88:239–243. [PubMed: 12181213]
30. MacGowan GA, Janosko K, Cecchetti A, Murali S. Exercise-related ventilatory abnormalities and survival in congestive heart failure. *Am J Cardiol*. 1997; 79:1264–1266. [PubMed: 9164901]
31. Robbins M, Francis G, Pashkow FJ, Snader CE, Hoercher K, Young JB, et al. Ventilatory and heart rate responses to exercise: Better predictors of heart failure mortality than peak oxygen consumption. *Circulation*. 1999; 100(24):2411–2417. [PubMed: 10595953]

Figure 1. Kaplan-Meier curves for patients achieving ≥ 33 or < 33 for the lowest VE/VCO_2 ratio ($p < 0.01$). Numbers given along the curves are cumulative numbers of composite outcomes; numbers in parentheses are patients evaluated at each time point.

Table 1

Mean values for demographic, clinical, and exercise test data, and associated univariate hazard ratios for death or transplantation through 3 years

	Mean±SD	Hazard Ratio (95% CI)	<i>p-value</i>
Demographic characteristics			
Age (yr)	57 ± 14	1.01 (0.99–1.02)	0.22
Height (cm)	171 ± 10	1.01 (0.99–1.03)	0.48
Weight (kg)	84 ± 20	0.98 (0.97–0.99)	<0.001
Body-mass index (kg/m ²)	28.4 ± 5.9	0.93 (0.90–0.97)	<0.001
Clinical characteristics (%)			
LVEF	32.1 ± 14.1	0.96 (0.95–0.98)	<0.001
Beta-blocker	66.6	0.69 (0.47–1.02)	0.06
ACEI	73.6	1.4 (0.91–2.17)	0.12
Diuretic	80.8	1.7 (0.89–3.21)	0.10
Aldosterone Antagonist	27.6	1.22 (0.80–1.88)	0.35
Exercise test responses			
Maximal heart rate (beats.min ⁻¹)	127 ± 21	0.98 (0.97–0.99)	<0.001
Maximal SBP (mmHg)	154 ± 38	0.99 (0.98–1.00)	0.09
Peak VO ₂ (ml/kg/min)	15.1 ± 4.9	0.89 (0.89–0.93)	<0.0001
% age-predicted peak VO ₂	59.7 ± 19	0.97 (0.97–0.98)	<0.0001
Lowest VE/VCO ₂ ratio	35.2 ± 7.6	1.06 (1.04–1.08)	<0.0001
VE/VCO ₂ slope	35.7 ± 8.3	1.07 (1.05–1.08)	<0.0001
Maximal RER	1.08 ± 0.12	1.52 (0.32–7.10)	0.60

All variables except medications are expressed continuously; hazard ratios for all variables except medications are for a 1-unit increase.

LVEF, left ventricular ejection fraction; ACEI, angiotensin converting enzyme inhibitor; SBP, systolic blood pressure; RER, respiratory exchange ratio.

Table 2

Area under the receiver operator characteristic curve (AUC) and optimal thresholds for peak VO₂, the VE/VCO₂ slope, and lowest VE/VCO₂ ratio

		<i>P</i>	Optimal		
	AUC	Value*	Threshold	Sensitivity	Specificity
Lowest VE/VCO ₂ ratio	0.67	<0.001	</ 33	79%	52%
VE/VCO ₂ slope	0.68	<0.001	</ 34	74%	57%
Peak VO ₂	0.67	<0.001	</ 14	73%	54%

AUC, area under the ROC curve

* AUC values did not differ from one another; p value refers to whether accuracy of each test differed from chance

Demographic characteristics and exercise test responses for subjects above and below the threshold values for lowest VE/VCO₂ ratio, VE/VCO₂ slope and peak VO₂.

Table 3

	Lowest VE/VCO ₂ ratio		P	VE/VCO ₂ slope		P	Peak VO ₂ (ml/kg/min)		P
	< 33	33 (N = 496)		< 34 (N = 413)	34 (N = 434)		< 14 (N = 382)	14 (N = 465)	
Demographic characteristics			VALUE			VALUE			VALUE
Age (yrs)	55 ± 13	59 ± 14	<0.001	54 ± 14	60 ± 13	<0.001	59 ± 13	56 ± 14	<0.001
Height (cm)	171.6 ± 9.8	170.7 ± 10.2	0.19	172 ± 10	170 ± 9	0.02	169 ± 10	173 ± 10	<0.001
Weight (kg)	87.7 ± 20.7	81.0 ± 19.8	<0.001	87.8 ± 22.1	79.7 ± 18.0	<0.001	83.0 ± 20.4	84.4 ± 20.5	0.32
Body-mass index	29.6 ± 27.6	27.6 ± 5.8	<0.001	29.5 ± 6.3	27.4 ± 5.3	<0.001	29.0 ± 6.3	28.0 ± 5.6	0.02
Resting values									
Heart rate (beats.min ⁻¹)	75 ± 12	75 ± 14	0.93	75 ± 13	75 ± 14	0.86	77 ± 14	74 ± 12	0.02
Blood Pressure (mm Hg)									
Systolic	122 ± 28	122 ± 26	0.93	124 ± 25	122 ± 26	0.56	126 ± 27	120 ± 26	0.02
Diastolic	74 ± 15	72 ± 13	0.32	74 ± 12	72 ± 13	0.29	74 ± 12	72 ± 15	0.17
Maximal values									
Heart rate (beats.min ⁻¹)	134 ± 20	122 ± 21	<0.001	132 ± 21	123 ± 21	<0.001	118 ± 20	135 ± 19	<0.001
Blood Pressure (mm Hg)									
Systolic	163 ± 37	149 ± 37	<0.001	163 ± 33	148 ± 37	<0.001	151 ± 39	156 ± 37	0.15
Diastolic	79 ± 19	76 ± 19	0.17	79 ± 16	76 ± 20	0.08	78 ± 18	77 ± 20	0.54
Ventilatory responses									
Peak VO ₂ (mL.kg ⁻¹ .min ⁻¹)	17.2 ± 5.2	13.6 ± 4.1	<0.001	16.8 ± 5.2	13.4 ± 4.0	<0.001	11.0 ± 2.1	18.4 ± 4.0	<0.001
VE/VCO ₂ slope	29.9 ± 3.9	39.7 ± 8.2	<0.001	29.4 ± 3.0	41.5 ± 7.5	<0.001	38.9 ± 9.4	32.9 ± 6.1	<0.001
Lowest VE/VCO ₂ ratio	28.9 ± 2.7	39.6 ± 6.9	<0.001	30.3 ± 4.0	39.7 ± 7.5	<0.001	38.3 ± 8.5	32.6 ± 5.7	<0.001

Values are mean ± SD. P values are for comparisons between cut-points in each group.

Table 4

Age-adjusted Akaike Information Criteria (AIC) weights for models using peak VO_2 , VE/VCO_2 slope, and lowest VE/VCO_2 ratio separately, paired, and combined

	AIC weight
Model 1	<0.01
Peak $\text{VO}_2 < 14$	
Model 2	<0.01
slope VE/VCO_2	
Lowest VE/VCO_2 ratio	
Model 3	<0.01
Peak $\text{VO}_2 < 14$	
slope VE/VCO_2	
Lowest VE/VCO_2 ratio	
Model 4	0.05
Peak $\text{VO}_2 < 14$	
slope VE/VCO_2	
Lowest VE/VCO_2 ratio	
Model 5	<0.01
Peak $\text{VO}_2 < 14$	
slope VE/VCO_2	
Lowest VE/VCO_2 ratio	
Model 6	0.02
Peak $\text{VO}_2 < 14$	
slope VE/VCO_2	
Lowest VE/VCO_2 ratio	
Model 7	0.94
Peak $\text{VO}_2 < 14$	
slope VE/VCO_2	
Lowest VE/VCO_2 ratio	

Table 5

Hazard ratios for death and transplantation associated with abnormal peak VO_2 , VE/VCO_2 slope, lowest VE/VCO_2 ratio, and their combination*

Exercise Test Response	Description	Hazard ratio	95% CI	P value	% Event free (95% CI)
Peak VO_2 (ml/kg/min) 14	All responses normal	1 (reference)	-	-	
VE/VCO_2 slope < 34	(n=218; #events=9)				96 (92–99)
Lowest VE/VCO_2 < 33					
Peak VO_2 (ml/kg/min) 14	Lowest VE/VCO_2 ratio abnormal only	3.08	1.03 – 9.17	0.04	
VE/VCO_2 slope < 34	(n=56; #events=11)				80 (64–96)
Lowest VE/VCO_2 33					
Peak VO_2 (ml/kg/min) 14	VE/VCO_2 slope abnormal only	4.94	1.44 – 16.98	<0.001	
VE/VCO_2 slope > 34	(n=32; #events=6)				80 (61–99)
Lowest VE/VCO_2 < 33					
Peak VO_2 (ml/kg/min) < 14 and	Peak VO_2 abnormal only	3.25	1.17 – 8.99	0.02	
VE/VCO_2 slope < 34 and	(n=77; #events=12)				85 (76–95)
Lowest VE/VCO_2 < 33					
Peak VO_2 (ml/kg/min) < 14 and	Peak VO_2 and VE/VCO_2 slope abnormal	5.30	1.55 – 18.14	0.008	
VE/VCO_2 slope 34 and	(n=29; #events=6)				81 (64–98)
Lowest VE/VCO_2 < 33					
Peak VO_2 (ml/kg/min) < 14 and	Peak VO_2 and lowest VE/VCO_2 ratio abnormal	5.52	2.10 – 14.50	<0.001	
VE/VCO_2 slope < 34 and	(n=53; #events=15)				72 (57–88)
Lowest VE/VCO_2 33					
Peak VO_2 (ml/kg/min) 14 and	VE/VCO_2 slope and lowest VE/VCO_2 ratio abnormal	7.10	3.11 – 16.21	<0.001	
VE/VCO_2 slope 34 and	(n=154; #events=52)				66 (56–77)
Lowest VE/VCO_2 33					
Peak VO_2 (ml/kg/min) < 14 and	All 3 abnormal	11.62	5.28 – 25.57	<0.001	
VE/VCO_2 slope 34 and	(N=228; #events=96)				58 (49–67)
Lowest VE/VCO_2 33					

Author Manuscript
Adjusted for age and one another
*

Author Manuscript

Author Manuscript

Author Manuscript